Literature DB >> 26421474

Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.

F Palma1, A Volpe1, P Villa2, A Cagnacci3.   

Abstract

OBJECTIVES: Prevalence of vulvar-vaginal atrophy (VVA) has been always investigated by phone or web interview without any objective evaluation. Objective signs associated with symptoms of VVA are now termed genitourinary syndrome of menopause (GSM). This multi-centric study was performed in order to provide nation-wide data on the prevalence and management of GSM.
METHODS: Nine hundred thirteen females, 59.3 ± 7.4 years old asking for a routine gynecological examination were recruited. Diagnosis of GSM was based on patient sensation of vaginal dryness, any objective sign of VVA and a pH > 5.
RESULTS: A 722/913 (79.1%) women were diagnosed with GSM with a prevalence ranging from 64.7% to 84.2%, starting from 1 to 6 years after menopause. Sedentary women were at higher risk of GSM (OR 1.8, 95% CI: 1.3-2.5; p = 0.0005). Recent vaginal infection was more likely in women with GSM (OR 2.48, 95% CI: 1.33-4.62; p = 0.0041). Symptoms reported by women with GSM were vaginal dryness (100%), dyspareunia (77.6%), burning (56.9%), itching (56.6%) and dysuria (36.1%). Signs detected by gynecologists were mucosal dryness (99%), thinning of vaginal rugae (92.1%), pallor of the mucosa (90.7%), mucosal fragility (71.9%) and petechiae (46.7%). Only 274 (30%) of women had had a previous diagnosis of VVA/GSM. These were treated either with no therapy (9.8%), systemic hormone (9.2%), local hormone (44.5%) or local non-hormonal (36.5%) therapy. At the time of our investigation 266 of them (97.1%) still had the disorder.
CONCLUSIONS: GSM is a common, under-diagnosed and under-treated disorder. Measures to improve its early detection and its appropriate management are needed.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Genitourinary syndrome of menopause (GSM); Hormone therapy; Postmenopausal women; Vaginal atrophy; Vaginal therapy

Mesh:

Substances:

Year:  2015        PMID: 26421474     DOI: 10.1016/j.maturitas.2015.09.001

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  18 in total

1.  Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?

Authors:  Eleni Pitsouni; Themos Grigoriadis; Matthew Falagas; Angeliki Tsiveleka; Stefano Salvatore; Stavros Athanasiou
Journal:  Lasers Med Sci       Date:  2017-08-02       Impact factor: 3.161

Review 2.  Female Sexual Function at Midlife and Beyond.

Authors:  Holly N Thomas; Genevieve S Neal-Perry; Rachel Hess
Journal:  Obstet Gynecol Clin North Am       Date:  2018-10-25       Impact factor: 2.844

3.  Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?

Authors:  Anastasios Tranoulis; Dimitra Georgiou; Lina Michala
Journal:  Int Urogynecol J       Date:  2019-07-18       Impact factor: 2.894

4.  Clinical trial shows lasting function of a new moisturizing cream against vaginal dryness.

Authors:  Hans-Heinrich Henneicke-von Zepelin; Ragna Williams; Wiebke Havemeister; Walter Wigger-Alberti; Klaus-Ulrich Nolte
Journal:  Wien Med Wochenschr       Date:  2017-01-13

Review 5.  Putative functions of tissue kallikrein-related peptidases in vaginal fluid.

Authors:  Carla M J Muytjens; Stella K Vasiliou; Katerina Oikonomopoulou; Ioannis Prassas; Eleftherios P Diamandis
Journal:  Nat Rev Urol       Date:  2016-09-07       Impact factor: 14.432

Review 6.  Deconstructing the genitourinary syndrome of menopause.

Authors:  Pedro Vieira-Baptista; Claudia Marchitelli; Hope K Haefner; Gilbert Donders; Faustino Pérez-López
Journal:  Int Urogynecol J       Date:  2017-03-14       Impact factor: 2.894

7.  The silent epidemic of urogenital atrophy.

Authors:  Paula Briggs; Gayathri Delanerolle; Rachel Burton; Jian Qing Shi; Haitham Hamoda; Dharani K Hapangama
Journal:  Br J Gen Pract       Date:  2021-11-25       Impact factor: 5.386

8.  The mysteries of menopause and urogynecologic health: clinical and scientific gaps.

Authors:  Marianna Alperin; Lindsey Burnett; Emily Lukacz; Linda Brubaker
Journal:  Menopause       Date:  2019-01       Impact factor: 2.953

Review 9.  Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.

Authors:  Rossella E Nappi; Nicoletta Biglia; Angelo Cagnacci; Costantino Di Carlo; Stefano Luisi; Anna Maria Paoletti
Journal:  Gynecol Endocrinol       Date:  2016-05-17       Impact factor: 2.260

10.  Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women.

Authors:  César Arroyo
Journal:  Int J Womens Health       Date:  2017-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.